If you or someone you love has just been told their ovarian cancer has come back, you've probably heard your oncologist use the words "platinum-sensitive" or "platinum-resistant" and nodded along while quietly panicking about what it actually means. You're not alone — loads of us here have been there. Here's a plain-English rundown of what these terms mean and why they matter so much for what happens next.
Why "platinum" in the first place?
Most ovarian cancer treatment starts with platinum-based chemotherapy (drugs like carboplatin), usually alongside surgery. It works well for a lot of women initially, but ovarian cancer has an unfortunately high chance of coming back at some point. When it does, doctors look closely at how long it's been since your last platinum chemo finished — because that timing tells them a lot about how the cancer is likely to behave next.
Platinum-sensitive: the cancer came back after a longer gap
If your cancer recurs 6 months or more after you finished platinum chemo, it's generally classed as platinum-sensitive. This is the better-case scenario, relatively speaking — it suggests the cancer cells may still respond to platinum drugs, so going back onto a platinum-based combination is often back on the table. Common combinations include:
- Carboplatin + paclitaxel
- Carboplatin + gemcitabine
- Carboplatin + pegylated liposomal doxorubicin (PLD)
- Sometimes with bevacizumab added in for certain patients
If you've had genetic testing showing a BRCA1/2 mutation, or your tumour is HRD-positive, your team might also talk to you about a PARP inhibitor as a "maintenance" treatment afterwards, to help keep things at bay for longer.
Platinum-resistant: the cancer came back sooner
If the cancer recurs or progresses
within 6 months of finishing platinum treatment, it's usually classed as platinum-resistant. This is harder to treat, because going back to another platinum regimen tends not to work as well the second time. Doctors will usually steer towards non-platinum options instead, such as:
- Paclitaxel
- Pegylated liposomal doxorubicin
- Topotecan
- Bevacizumab, in some patients
- Newer biomarker-led treatments
There's also a term you might hear —
platinum-refractory — which describes cancer that actually keeps progressing
while you're still having platinum chemo. This is the most difficult group to treat, and platinum drugs generally aren't continued in that situation.
One newer option worth knowing about: FRα-targeted therapy
For some women with platinum-resistant ovarian cancer, doctors may test the tumour for something called FRα (folate receptor alpha). If it's present, a newer type of drug called an antibody-drug conjugate — mirvetuximab soravtansine — has become an option for certain patients. It's one of a growing number of more targeted treatments beyond standard chemo, so it's worth asking your oncologist whether biomarker testing (BRCA, HRD, FRα) has been done or is worth doing, as it can open up options you might not otherwise be offered.
The 6-month rule isn't set in stone
It's a useful guide, not a strict cut-off. Your actual treatment plan will depend on lots of things beyond just the timing — how you responded to treatment before, how much disease there is now, your general health, and what your specific tumour biology shows up on testing.
The bottom line
These labels — sensitive, resistant, refractory — aren't a verdict, they're a starting point for a conversation with your oncology team about what's likely to work best next. If you're newly facing a recurrence, it's absolutely worth asking directly:
"Are we treating this as platinum-sensitive or resistant, and why?" — it'll help you understand the reasoning behind whatever plan they suggest, and what other options (like biomarker testing) might be worth raising.
Sending strength to anyone going through this. 💛
This post is for general information only and isn't a substitute for advice from your own medical team, who know your individual case.